Identification of a Potent and Selective GPR4 Antagonist as a Drug Lead for the Treatment of Myocardial Infarction
Hayato Fukuda(Kurume University), Satoshi Shuto, Chihiro Mogi, Kenji Watari(Sumitomo Dainippon Pharma (Japan)), Fumikazu Okajima(Aomori University), Hitoshi Kurose(Tokushima University), Saki Ito(Mayo Clinic in Arizona), Mitsuhiro Arisawa(Osaka University of Pharmaceutical Sciences)
Cited by 59
Related Papers
LTRPC2 Ca2+-Permeable Channel Activated by Changes in Redox Status Confers Susceptibility to Cell Death
|Molecular Cell|2002|830
Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via alpha-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells.
|Journal of Biological Chemistry|1983|497
TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophy
|The EMBO Journal|2006|417
Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound
|Proceedings of the National Academy of Sciences|2009|387